CARLSBAD, Calif.--(BUSINESS WIRE)--Advanced Brain Monitoring, Inc., a medical device company focused on improving healthcare for patients suffering from sleep and neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Night Shift, a therapy for positional obstructive sleep apnea.
Worn on the back of the neck, Night Shift begins to vibrate when users begin to sleep on their back and slowly increases in intensity until a position change occurs. Night Shift is also an intelligent, interactive monitor that allows users to track its affect on snoring and sleep quality. Clinical study results showed that 89% of participants responded to Night Shift therapy, with the majority experiencing improved sleep quality, reduced loud snoring and improvements in sleep apnea symptoms.
“In our study we found that 70% of individuals with obstructive sleep apnea are at least twice as severe while sleeping on their back and may benefit from Night Shift therapy,” stated Daniel Levendowski, principal investigator for the study. Most snore more loudly when sleeping on their back, an annoyance that interrupts the sleep of the bed partner.
Night Shift is immediately available through an Indiegogo crowdfunding campaign until June 22nd. The campaign allows participants to obtain the Night Shift at a substantially discounted price and includes a number of additional benefits.
About Advanced Brain Monitoring
Advanced Brain Monitoring, headquartered in Carlsbad, CA, is a privately held industry leader in sleep and neurotechnology with products that provide a superior patient experience, lower healthcare costs, and improve quality of care. The Company has been named to the Inc. 5000 fastest-growing U.S. companies for five consecutive years.
Contacts
Advanced Brain Monitoring, Inc.br> Daniel J. Levendowskibr> Presidentbr> 760-720-0099br> Dan@b-alert.combr> www.advanced-sleep.combr> www.nightshifttherapy.com
Help employers find you! Check out all the jobs and post your resume.
